ClinicalTrials.gg
CompletedNCT00486018BRAVOUpdated May 10, 2017Results posted

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

A Phase 3 interventional study of Ranibizumab injection 0.3 mg and Ranibizumab injection 0.5 mg in Macular Edema and Retinal Vein Occlusion, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
4th of 91
397 · median 50
Started
2007
with 8 others
Phase 3
25 of 91
none open now
Registered
8th of 91
by date
Lead sponsor
7 of 91
Genentech, Inc.

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 4th largest by enrollment, is one of 9 that started in 2007, is one of 25 in phase 3, and was the 8th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO); 397 patients with BRVO were enrolled at 93 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).

03

Conditions studied

  • Macular Edema
  • Retinal Vein Occlusion

Keywords

  • Lucentis
  • RVO
  • BRVO
  • Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to provide signed Form
  • Age ≥ 18 years
  • For sexually active women of , use of an appropriate form of (or abstinence) for the duration of the study
  • Ability and willingness to return for all scheduled visits and assessments

Ocular Inclusion Criterion (Study Eye):

  • Foveal center-involved macular edema secondary to BRVO
  • BCVA using ETDRS charts of 20/40 to 20/400 (Snellen equivalent)
  • Mean central subfield thickness ≥ 250 μm on two optical coherence tomography (OCT) measurements (at screening [confirmed by the central reading center] and Day 0 [confirmed by the evaluating physician])
  • Media clarity, pupillary dilation, and participant cooperation sufficient to obtain adequate fundus photographs

Exclusion criteria

Exclusion Criteria:

  • History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0
  • History of any anti-vascular endothelial growth factor (VEGF) treatment in fellow eye within 3 months prior to Day 0
  • History of any systemic anti-VEGF or pro-VEGF treatment within 6 months prior to Day 0
  • History of allergy to fluorescein
  • History of allergy to ranibizumab injection or related molecule
  • Relevant systemic disease that may be associated with increased systemic VEGF levels (namely, all active ); history of successfully treated malignancies is not an exclusion criterion
  • Uncontrolled blood pressure
  • Pregnancy or lactation
  • Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of major tranquilizers, indicated difficulty in long-term follow-up, and likelihood of survival of less than 1 year)
  • Participation in an trial within 30 days prior to Day 0 that involved treatment with any drug (excluding vitamins and minerals) or device that has not received regulatory approval at time of study entry

Ocular Exclusion Criteria (Study Eye):

  • Prior episode of retinal vein occlusion (RVO)
  • Brisk afferent pupillary defect
  • History of radial optic neurotomy or sheathotomy
  • History or presence of age-related macular degeneration (AMD; dry or wet form)
  • History of any anti-VEGF treatment in the study eye within 3 months prior to Day 0
  • History of laser photocoagulation for macular edema within 4 months prior to Day 0
  • History of panretinal scatter photocoagulation or sector laser photocoagulation within 3 months prior to randomization or anticipated within the next 4 months following randomization
  • History of intraocular use within 3 months prior to Day 0
  • History of pars plana vitrectomy
  • History of intraocular surgery (including cataract extraction, scleral buckle, etc.) within 2 months prior to Day 0 or anticipated within the next 7 months following Day 0
  • History of yttrium-aluminum-garnet capsulotomy performed within 2 months prior to Day 0
  • Previous filtration surgery in the study eye
  • History of herpetic ocular infection
  • History of ocular toxoplasmosis
  • History of rhegmatogenous retinal detachment
  • History of idiopathic central serous chorioretinopathy
  • Evidence upon examination of vitreoretinal interface disease (e.g., vitreomacular traction, epiretinal membrane), either on clinical examination or OCT, thought to be contributing to macular edema
  • An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates
  • Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the study (e.g., uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, or prior macula-off rhegmatogenous retinal detachment)
  • Visually significant hemorrhage obscuring the fovea and felt to be a major contributor to reduced visual acuity
  • Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract)
  • Aphakia
  • Relevant ocular disease that may be associated with increased intraocular VEGF levels (namely, uveitis, neovascular glaucoma, neovascular AMD, diabetic retinopathy, diabetic maculopathy, or ocular ischemic syndrome)
  • Improvement of > 10 letters on best corrected visual acuity (BCVA) between screening and Day 0
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
397 participants (actual)

Study arms

  • Sham comparator
    Sham injection

    Drug: Sham injection

  • Experimental
    Ranibizumab injection 0.3 mg

    Drug: Ranibizumab injection 0.3 mg

  • Experimental
    Ranibizumab injection 0.5 mg

    Drug: Ranibizumab injection 0.5 mg

Interventions

  • Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

    Also known as: Lucentis

  • Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

    Also known as: Lucentis

  • DrugSham injection

    Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months

    BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline

    BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.

    Time frame: Baseline and 6 months

  2. Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline

    BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters. The percentage of subjects who lost \<15 letters will be greater than the percentage of subjects who "gained \>=15 letters" as "losing \<15 letters" includes both those who gained \>=15 letters and those who were "stable" (i.e. lost between 1 and 14 letters, had no change, or gained between 1 and 14 letters).

    Time frame: Baseline and 6 months

  3. Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6

    A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.

    Time frame: 6 months

  4. Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6

    A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.

    Time frame: Baseline and 6 months

  5. Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6

    The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.

    Time frame: Baseline and 6 months

  6. Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6

    The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.

    Time frame: Baseline and 6 months

07

Results

Posted Feb 25, 2011

Participant flow

Please note that although the table below is titled "Overall Study," the completion rates are for the 6-month Treatment Period only (i.e., does not include the 6-month Observation Period data).

Participant flow — Overall Study
MilestoneSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Started132134131
Received drug (safety population)131134130
Completed123128125
Not completed966

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months

BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.

Time frame:
Baseline and 6 months
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months
Units on a scaleSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Baseline54.7 ± 12.256.0 ± 12.153.0 ± 12.5
Change from Baseline at Month 67.3 ± 13.016.6 ± 11.018.3 ± 13.2
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · ANOVA · p = <0.0001 (The Hochberg-Bonferroni multiple comparison procedure was used to adjust for comparisons of the two ranibizumab groups with the sham-injection group to maintain an overall type I error rate of 0.05.) · Difference in least squares means: 9.4 · 95% CI 6.6 to 12.2Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).
  • Sham Injection vs Ranibizumab Injection 0.5 mg · ANOVA · p = <0.0001 (The Hochberg-Bonferroni multiple comparison procedure was used to adjust for comparisons of the two ranibizumab groups with the sham-injection group to maintain an overall type I error rate of 0.05.) · Difference in least squares means: 10.6 · 95% CI 7.6 to 13.6Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).
SecondaryPercentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline

BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.

Time frame:
Baseline and 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline
Percentage of participantsSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline28.8 (21.1 to 36.5)55.2 (46.8 to 63.6)61.1 (52.7 to 69.4)
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · Cochran-Mantel-Haenszel χ² · p = <0.0001 · Difference in percentage: 26.8 · 95% CI 15.6 to 38.0Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.
  • Sham Injection vs Ranibizumab Injection 0.5 mg · Cochran-Mantel-Haenszel χ² · p = <0.0001 · Difference in percentage: 31.3 · 95% CI 20.1 to 42.6Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.
SecondaryPercentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline

BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters. The percentage of subjects who lost \<15 letters will be greater than the percentage of subjects who "gained \>=15 letters" as "losing \<15 letters" includes both those who gained \>=15 letters and those who were "stable" (i.e. lost between 1 and 14 letters, had no change, or gained between 1 and 14 letters).

Time frame:
Baseline and 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline
Percentage of participantsSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline95.5 (90.5 to 98.0)100 (97.4 to 100)98.5 (94.6 to 99.7)
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · Fisher Exact · p = 0.0141 · Difference in percentage: 4.5 · 95% CI 1.6 to 9.9Exact confidence interval based on inverting the exact two-sided score test.
  • Sham Injection vs Ranibizumab Injection 0.5 mg · Fisher Exact · p = 0.2815 · Difference in percentage: 3.0 · 95% CI -1.5 to 8.3Exact confidence interval based on inverting the exact two-sided score test.
SecondaryPercentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6

A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6
Percentage of participantsSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 645.5 (37.0 to 53.9)91.0 (86.2 to 95.9)84.7 (78.6 to 90.9)
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · Cochran-Mantel-Haenszel χ² · p = <0.0001 · Difference in percentage: 45.5 · 95% CI 36.0 to 55.0Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.
  • Sham Injection vs Ranibizumab Injection 0.5 mg · Cochran-Mantel-Haenszel χ² · p = <0.0001 · Difference in percentage: 40.1 · 95% CI 29.9 to 50.2Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.
SecondaryMean Absolute Change From Baseline in Central Foveal Thickness at Month 6

A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.

Time frame:
Baseline and 6 months
Reported as:
Mean · μm
Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6
μmSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Baseline488.0 ± 192.2522.1 ± 201.9551.7 ± 223.5
Mean Absolute Change from Baseline at Month 6-157.7 ± 224.2-337.3 ± 224.4-345.2 ± 238.2
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · ANCOVA · p = <0.0001 · Difference in least squares means: -148.7 · 95% CI -183.6 to -113.8Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline value of central foveal thickness.
  • Sham Injection vs Ranibizumab Injection 0.5 mg · ANCOVA · p = <0.0001 · Difference in least squares means: -134.8 · 95% CI -172.7 to -96.8Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline value of central foveal thickness.
SecondaryMean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6

The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.

Time frame:
Baseline and 6 months
Reported as:
Mean · Points on the NEI VFQ-25 subscale
Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6
Points on the NEI VFQ-25 subscaleSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Baseline69.6 ± 20.267.9 ± 22.169.4 ± 20.5
Change from baseline at Month 67.3 ± 15.312.1 ± 17.313.7 ± 18.0
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · ANCOVA · p = 0.0214 · Difference in least squares means: 4.1 · 95% CI 0.6 to 7.6Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Near Activities Subscale score.
  • Sham Injection vs Ranibizumab Injection 0.5 mg · ANCOVA · p = 0.0002 · Difference in least squares means: 6.4 · 95% CI 3.0 to 9.8Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Near Activities Subscale score.
SecondaryMean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6

The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.

Time frame:
Baseline and 6 months
Reported as:
Mean · Points on the NEI-VFQ-25 subscale
Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6
Points on the NEI-VFQ-25 subscaleSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Baseline76.4 ± 20.676.0 ± 20.576.7 ± 18.1
Mean Change from Baseline at Month 66.3 ± 15.010.3 ± 17.211.3 ± 16.6
Statistical analysis
  • Sham Injection vs Ranibizumab Injection 0.3 mg · ANCOVA · p = 0.0248 · Difference in least squares means: 3.8 · 95% CI 0.5 to 7.0Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Distance Activities Subscale score.
  • Sham Injection vs Ranibizumab Injection 0.5 mg · ANCOVA · p = 0.0014 · Difference in least squares means: 5.1 · 95% CI 2.0 to 8.3Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Distance Activities Subscale score.

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham Injection—6/131 (4.6%)115/131 (87.8%)
Ranibizumab Injection 0.3 mg—14/134 (10.4%)125/134 (93.3%)
Ranibizumab Injection 0.5 mg—14/130 (10.8%)115/130 (88.5%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
PneumoniaInfections and infestations1/1312/1340/130
HypertensionVascular disorders0/1312/1340/130
Acute Myocardial InfarctionCardiac disorders0/1310/1341/130
Angina UnstableCardiac disorders0/1310/1341/130
BradycardiaCardiac disorders0/1310/1341/130
Gaze PalsyEye disorders0/1310/1341/130
Retinal Vein OcclusionEye disorders0/1310/1341/130
Colonic PolypGastrointestinal disorders0/1310/1341/130
Small Intestinal ObstructionGastrointestinal disorders0/1311/1341/130
Intestinal PerforationGastrointestinal disorders0/1310/1341/130
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mg
Conjunctival HemorrhageEye disorders55/13180/13471/130
Retinal ExudatesEye disorders20/13137/13432/130
Eye PainEye disorders19/13133/13421/130
Retinal HemorrhageEye disorders18/13123/13423/130
Ocular Vascular DisorderEye disorders16/13121/13410/130
MyodesopsiaEye disorders2/13117/1346/130
MaculopathyEye disorders11/13116/13416/130
Retinal DepigmentationEye disorders6/1316/13415/130
Retinal Vascular DisorderEye disorders9/13110/13415/130
Ocular HyperemiaEye disorders6/13113/1348/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mgTotal
Mean65.2 ± 12.766.6 ± 11.267.5 ± 11.866.4 ± 11.9
Age, Customized
Age, Customized(participants)Sham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mgTotal
< 45 years85417
45 to < 65 years595151161
65 to < 85 years607469203
≥ 85 years54716
Sex: Female, Male
Sex: Female, Male(Participants)Sham InjectionRanibizumab Injection 0.3 mgRanibizumab Injection 0.5 mgTotal
Female586760185
Male746771212
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Suner IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmol. 2013 Jul;131(7):851-6. doi: 10.1001/jamaophthalmol.2013.114. PubMed 23699977 ↗
  • Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology. 2013 May;120(5):1057-63. doi: 10.1016/j.ophtha.2012.11.011. Epub 2013 Feb 14. PubMed 23415775 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of May 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 9 months after primary completion. A results delay was requested in May 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2007
First posted
Jun 13, 2007
Start
Jul 2007
Primary completionActual
May 2009
CompletionActual
Nov 2009
Results delay requested
May 5, 2010
Results first posted
Feb 25, 2011
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00486018
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2007
Start date
Jul 2007
Primary completion
May 2009
Completion
Nov 2009
Results posted
Feb 25, 2011
Last update
May 10, 2017

Study contacts

Roman Rubio, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion